Our World Vaccine Congress in Barcelona is now next week and our start-up zone has reached capacity! This week we are delighted to introduce another batch of organisations that have secured their slots in the zone. To see previous introductions head over to our technology section.   

Why be a start-up at the World Vaccine Congress?    

Start-ups whose applications are successful are entitled to several unique benefits, including exhibition wall space, 2 complimentary passes, and marketing materials. For the first time at this event, there is the opportunity to participate in a 5-minute pitch during lunch breaks, an exciting way of introducing yourselves to colleagues and potential partners.     

Our wonderful start-up manager, Isabella Aung, has marshalled the start-up zone from its opening and will be on site to support each organisation. 

“I am super excited to connect with and welcome even more start-ups to our start-up zone at our Congress this October! It’s going to be our biggest and most exciting start-up zone yet!” 
  • A partner for in-silico discovery and optimisation of antibodies, biologics, and proteins. The team has assisted pharmaceutical companies and biotechs across a range of protein engineering and drug discovery programmes using cutting-edge technology.
  • With state-of-the-art AI/ML algorithms, coupled with in-silico pipelines and workflows, SilicoGenesis can rapidly develop new therapeutic lead molecules.
  • The technology covers the full scope of the pre-clinical drug discovery pipeline and the team’s scalable cloud-based software platform integrates their machine learning models, workflows, and pipelines with visualisation and project management functionality to operate at speed and scale.
  • The team combines expertise from various disciplines, including machine learning and artificial intelligence, data science, biochemistry, computational biology, and software engineering.
Serendip Innovations
  • Based in France, Serendip aims to potentiate peptide-based cancer vaccines using a proprietary drug delivery technology. This innovation, developed within the CNRS, is a unique modular Virus-Like Particle (VLP) derived from a plant virus. It is produced in a plant-based expression system, which allows a safe, flexible, and cost-effective production.
  • The design flexibility of VLP vaccines enables an engineered cocktail of tumour antigens to be specifically delivered in-vivo to dendritic cells (DCs). By designing the future vaccines, Serendip’s approach aims to induce a robust and long-lasting anti-tumour cytotoxic response.
  • Mainly by genetic fusion and specific ligand interaction, the internal cavity and the external surface are customised. While tumour antigens are encapsulated inside the VLP, ensuring their protection, a targeting nanobody or antibody is displayed on the surface of the VLP, enabling the VLP routing, its uptake, antigen processing, and peptide presentation to naïve T cells through the Major Histocompatibility Complexes (MHC).
  • Serendip’s roadmap objectives are to demonstrate the therapeutic clinical potential of the technology before initiating technology/products licensing and vaccine co-development partnerships with pharmaceutical and biotech companies.
Proxi biotech
  • A biotech company based in Denmark, focused on developing next-generation vaccines targeting bacterial infections to combat antimicrobial resistance. Using the team’s proprietary BACTOVAC technology they develop safe and highly immunogenic toxoid antigens for superior vaccines.
  • The BACTOVAC technology detoxifies bacterial toxins in a rapid, easy, and gentle manner, preserving critical structural epitopes that result in highly immunogenic vaccines.
  • Proxi’s lead vaccine targeting Clostridioides difficile infection has demonstrated perfect safety, superiority to benchmark, and 100% efficacy and survival in a gold standard challenge model.
  • Several new vaccine candidates are currently in the pre-clinical development pipeline.
  • Meclinas is a new research unit based in Mechelen (Belgium), specialising in Phase II and III clinical studies for ambulatory drugs and vaccinations.
  • With fast start-up timelines, reliable recruitment, and high quality, the team values respect, for the expectations of the clients, the well-being of participants, and staff satisfaction. This translates into quality and transparency.
  • Registered in Hanoi (Vietnam), in January 2019, C-Cube joins Swiss pharmaceutical engineering with Asean operations. The team has an optimised platform to develop the concept of intelligent, modular facilities for the life sciences industry on a global scale.
  • The vision is to facilitate health deployment around the world through an innovative and mobile facility concept.

Stay tuned for more start-up news, and make sure you subscribe to our weekly newsletters!